Inogen reported breakeven earnings for Q2 2026, beating the Zacks Consensus Estimate by 17.7%. This compares to an adjusted loss of 2 cents per share in the prior-year quarter. Revenues reached $95.1 million, up 3% year over year and slightly ahead of estimates. The growth was driven by strong international demand for portable oxygen concentrators, favourable exchange rates and new product contributions. International sales climbed 14.8% to $41.3 million, marking the 10th consecutive quarter of double-digit growth. However, US sales declined 2.3% to $42.3 million, whilst US rental revenues fell 11.8% to $11.6 million. Adjusted gross margin improved 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Year to date, Inogen's shares have fallen 10%.

Inogen reported strong international revenue growth of 15% year-over-year in Q2 2026, marking its 10th consecutive quarter of double-digit international growth. The company's core portable oxygen concentrator unit volume grew over 12%, outpacing overall market growth. Gross margin expanded by 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Inogen raised its full-year adjusted EBITDA guidance to approximately $4 million, representing 48% growth over 2025. However, the company lowered its full-year revenue guidance to $355–361 million from $366–373 million. US sales declined 2% year-over-year due to channel mix challenges, whilst US rental revenue decreased 12%. New products Voxy and Aurora are gaining traction, with Voxy shipping over 5,000 units. Inogen maintains a strong balance sheet with $106.8 million in cash and no debt.

Yuwell Medical has announced a strategic investment in Inogen, a US-based respiratory health company. Through its Hong Kong subsidiary, Yuwell will invest approximately $27.2 million for a 9.9% stake in Inogen's common stock. The partnership will focus on four key areas: international distribution, trademark licensing, joint research and development, and supply chain optimisation. Both companies specialise in oxygen concentrators and aim to combine their expertise across different markets. At Yuwell's 2025 Global Core Partner Conference, Chairman Alex Wu outlined the company's five-year vision to become one of the top three global players in home medical health. Yuwell identified respiratory treatment solutions, diabetes care, and emergency services as its three strategic priorities for international expansion.